打开APP

美敦力推出世界最小可植入体内的心电图仪

  1. 可植入
  2. 心电图仪
  3. 美敦力

来源:northbay business journal 2014-03-24 09:38

瑞士美敦力欧洲总部全球媒体会日前举行,会上,美敦力首次展示刚刚推向市场的世界最小可植入体内的心电图仪。

这是一个尺寸只有两根火柴棍粗细的扁扁的小钢棍,放在塑料口袋里。

以前都是人得了病去医院诊断治疗,然后回到家中,等待下一次有病再来医院治疗。如果在体内安装了这个仪器,医院随时监控该慢性病患者的身体状况,通过数据分析,及时通知他来医院进行复查。这一方面可以使医生更好地管理慢性病患者,另一方面实现减少了患者看病的成本。” 据介绍,只要把这个小小的器材植入皮下,一头连着心脏,另一头则无线与医院的信息中心相联,可以随时监控患者心脏方面随时随地发出的信息,从而在较长的时间段里发现患者的心脏节律异常。(生物谷Bioon.com)

 

Monday, March 17, 2014, 6:50 am
St. Joseph doctors first in Bay Area to implant new Medtronic device
ab0ut the size of a AAA battery, the Medtronic Reveal LINQ cardiac monitor is inserted just beneath the skin in the upper chest area and continuously records heart rhythms over long periods of time.

SANTA ROSA — Cardiologists at two St. Joseph Health-affiliated facilities, Santa Rosa Memorial Hospital and the nearby Advanced Surgery Institute, recently implanted a new miniature cardiac monitoring device used to continuously and wirelessly monitor a patient’s heart, becoming the Bay Area’s first to offer the minimally invasive alternative to larger implants, officials said.

Officials from the health system said  the tiny implant made by Medtronic, called the Reveal LINQ Insertable Cardiac Monitor, is the world’s smallest implantable heart monitor. It measures ab0ut a third of the size of an AAA battery, and local Medtronic representatives confirmed the new monitors were the first of their kind to be implanted by any Bay Area provider, and among the first in the state.

“The LINQ is 80 percent smaller than other implantable cardiac monitors. That’s the main advantage,” said Dr. Peter Chang-Sing, medical director of Santa Rosa Memorial’s Cardiac Electrophysiology Lab and a member of Medtronic’s national electrophysiology advisory board.

The device is inserted using a syringe-like instrument during a 10-minute procedure under local anesthetic, as cardiologists place the monitor under the skin through a 1-centimeter incision in the chest.

No sutures are required and, once implanted, the device is nearly imperceptible to the naked eye. The monitor was cleared for U.S. use by the federal Food and Drug Administration on Feb. 19, this year to treat patients experiencing symptoms such as dizziness, palpitation, fainting and chest pain that may suggest a cardiac arrhythmia, and for patients at increased risk for cardiac arrhythmias, according to officials involved.

An arrhythmia is a disturbance in the heart’s normal rhythm, and there are many types – involving a too-slow heartbeat, too-rapid heartbeat, or an irregular heartbeat, for example. Many patients are “asymptomatic,” meaning their arrhythmia may represent a silent threat which they seldom if ever recognize on their own. The LINQ automatically detects an abnormal rhythm even if a patient doesn’t proactively activate it, said Dr. Thomas Dunlap, regional director of cardiac and vascular services at Santa Rosa Memorial.

“The beauty of this device is that it’s so small that it’s very atraumatic for the patient, while allowing us to very accurately assess whether a patient has a potentially life-threatening arrhythmia,” said Dr. Dunlap, who implanted the monitor in the first patient to receive one at Santa Rosa Memorial’s Heart & Vascular Institute. “You can obtain details ab0ut the patient’s heart rhythm in close to real time. Very quickly, it will transmit any rhythm disturbances to alert a clinician without the patient having to recognize any symptoms on his own, and it can distinguish between different types of arrhythmia.”

The device can be safely implanted even in patients who are taking anticoagulants, Dr. Dunlap added.

Through the device’s continuous monitoring, heart specialists can assess the efficacy of drug treatment or catheter ablation in patients who have arrhythmias such as atrial fibrillation, Dr. Chang-Sing said.

The simplicity of the implantation procedure increases patient comfort, convenience and safety, according to Ann Hurd, RN, administrator and director of nursing at the Advanced Surgery Institute where Dr. Chang-Sing implanted the center’s first Reveal LINQ monitor in a patient.  “With the smaller incision, it’s less invasive and lowers the risk of infection,” said Ms. Hurd of ASI, in which Santa Rosa Memorial owns a 51 percent share.

The device can wirelessly monitor a patient’s heart for up to three years, with 20 percent more data memory than its larger predecessor, Medtronic’s Reveal XT.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->